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1 INTRODUCTION 
 
The study of mesenchymal stem cells begun as early as 1867 (Prockop DJ 1997), when a 
German pathologist, J. Cohnheim studied the origins of cells participating in wound 
healing. Based on these results he proposed that cells capable of non-hematopoietic 
differentiation also derive from the bone marrow. 
 
Some 90 years later the Russian scientist Friedenstein identified a population of plastic 
adherent, in-vitro colony forming, fibroblast-like cells (colony forming unit (CFU) 
fibroblast) that were capable of osteogenesis under cultured conditions and form bone  
when ectopically planted in-vivo (Friedenstein, 1966; 1970; 1974). The terminology and 
definition of what Friedenstein called CFU-fibroblasts have since been changing during 
years and was first coined as mesenchymal stem cells (MSC) by Caplan in 1991 (Caplan 
AI 1991).  
 
We've come a long way from J. Cohnheims studies, but the field of stem cell research is 
hotter than ever, because still today, the goal for easily achievable stem cells for the use 
of tissue engineering and stem cell therapies, is yet to be achieved.  
 
The human adipose tissue is a complex innervated endocrine organ that composes of a 
variety of different cell types e.g. adipocytes, preadipocytes, blood cells, vascular tissue 
and so called adipose tissue-resident immune cells (ATRIC) (Rodbell M 1964; Hauner H 
et al. 1989; Weisberg SP et al. 2003; Lumeng CN et al. 2008). The many roles of an 
adipose tissue includes energy storage, mechanical support, thermal insulation and 
regulation of energy balance and glucose homeostasis (Bates et al. 2003; Berglund ED et 
al. 2012). 
 
In the present study, the performance of a human stem cell model of adipogenesis, 
induced with the use of a humane biological induction media, is evaluated.  As there is 
some coherence between the increasing obesity rates and the manifestation of synthetic 
endocrine disrupting chemicals (EDC) in our environment, bisphenol A (BPA), a known 
EDC, is used as a test substance (Casals-Casas C and Desvergne B 2010). 
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2 MESENCHYMAL STEM CELLS 
 
In an embryo, MSCs are located in the middle one of the three early embryonic germ 
layers, the mesoderm, and are the source of all of the body’s skeletal elements (Caplan 
AI, 1991). The Greek derived term, mesenchyme, means “middle” (meso) “infusion” 
(enchyma) and refers to the ability of these cells to spread and migrate between the germ 
layers in early embryonic development. 
 
Because of the wide disunity concerning the definition of MSCs, the International Society 
for Cellular Therapy (ISCT) suggested in 2006 the minimum criteria required to define 
MSCs (Dominici M. et al. 2006). By ISCT, the cells must: 
 
 Be adherent to plastics 
 Express the cell surface antigens CD105, CD73, and CD90 
 Not express the cell surface antigens CD45, CD34,CD14, CD11b, CD79α, CD19, 
or HLA-DR 
 Be able to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro 
 
The physiological precursors of MSCs are ubiquitous throughout the adult body, 
including the adipose tissue (I.R. Murray et al. 2014). One have to keep in mind that MSC 
defined this way are semisynthetic and that when we are talking about the MSCs found 
in their natural environment, we are actually referring to the biological precursors of the 
semisynthetic MSCs. 
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Figure 1. Gene expression during adipogenesis. BMP2 and/or BMP4 starts the adipogenic process in MSCs followed by three cytoskeleton related downstream targests, 
Lox, Tpt1 and αB crystalline. Next in the prosess is Wnt signaling activated by R-spondins 2 and -3. As the preadipocyte  stage developes towards terminal differentiation, 
the Wnt signaling gets  downregulated, allowing SERBP1c, C/EPBα and PPARγ to be expressed, thus finishing the apipogenic prosess. 
(Tang QQ et al. 2007; Huang H et al. 2009; Huang HY et al. 2011; Bowers RR and Lane MD, 2008; Ross SE et al. 2000; Bennet CN et al. 2005; Vertino AM et al. 2005; 
Christy RJ et al. 1989; Tontonoz P et al 1995; Schoonjans K et al 1996; Payne VA et al. 2010). BMP = bone morphogenetic protein; Lox = Lysyl oxidase; Tpt1 = 
translationally controlled tumor protein; Wnt = Wingless-type MMTV integration site family; SREBP =  sterol-regulatory-element-binding protein; C/EBP =  CCAAT-
enhancer binding protein; PPAR = peroxisome proliferator activated receptor.
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3 ADIPOGENESIS AND ADIPOSE TISSUE 
 
3.1 From MSCs to preadipocytes 
 
The very early steps from MSCs to adipogenic commitment have been studied with an 
MSC cell line, C3H/10T1/2 (Tang QQ et al. 2007; Huang H et al. 2009). Two recognized 
factors affecting adipogenic commitment are bone morphogenetic proteins 2 and 4 
(BMP2 and BMP4) and the Wingless-type MMTV integration site family (Wnt) signaling 
pathway (Figure 1.). 
 
Introducing BMP4 or BMP2 to dividing C3H/10T1/2 cells gives raise to preadipocyte-
like cells that can undergo adipogenesis when introduced to an adipogenic cocktail 
(Huang H et al. 2009). In addition, overexpression of a constitutively active BMP 
receptor, CA-BMPr1A or CA-BMPr1B in C3H/10T1/2 cells is enough for commitment 
and overexpression of a dominant negative BMP receptor, dominant-negative-BMPr1A, 
suppresses commitment induced by BMP (Huang HY et al. 2009). 
 
Three downstream target genes coding three cytoskeleton associated proteins, lysyl 
oxidase (Lox), translationally controlled tumor protein (Tpt1) and αB crystalline, gets 
upregulated more than10-fold in reaction to either BPA2 or -4. Adipocyte linage 
commitment gets completely blocked when Lox is inhibited and partially blocked when 
either Tpt1 or αB crystalline is inhibited (Huang HY et al. 2011). This suggests that BMP 
has a role in early cytoskeleton modification required for adipogenic differentiation.   
  
Wnt signaling has a role in adipogenesis both early on at commitment as well as later on 
in terminal differentiation (Bowers RR and Lane MD, 2008). The role of wnt in linage 
commitment of MSCs have been concluded form the differences in gene expression 
patterns in a MSC cell line, C3H/10T1/2 and a pre-adipocyte cell line, A33. Activators of 
the wnt signaling, R-spondins -2 and -3 were shown to be upregulated in A33 cells 
compared to C3H/10T1/2 cells. The downstream targets of the wnt signal, lymphoid 
enhancer factor and T-cell factor, were also found to be differentially expressed in A33 
preadipocytes in comparison to the CH3/10T1/2 MSC cells. These changes in gene 
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activity were concomitant with the accumulation of β-catenin, a key factor in the 
canonical wnt signaling pathway, in the nucleus. 
 
As the commitment phase is over and the terminal differentiation starts, the wnt signaling 
ceases conveniently, as it interferes with the terminal differentiation in several ways: 1) 
by inhibiting the expression of the two main terminal adipogenic factors CCAAT-
enhancer binding protein (C/EBP)-α and peroxisome proliferator activated receptor 
(PPAR)-γ; 2) by directing the differentiation towards other mesodermal cell fates and 3) 
by interfering with the obligatory clonal expansion phase (Ross SE et al. 2000; Bennet 
CN et al. 2005; Vertino AM et al. 2005). Thus while the role of the increased wnt activity 
during commitment is obscure, the role of its down regulation upon terminal 
differentiation seems somewhat clearer.  
 
3.2 From preadipocytes to adipocytes 
 
Probably the most used cell line in the study of terminal adipogenesis is the 1974 
established 3T3-L1 preadipocyte cell line (Green H and Kehinde O 1974). 3T3-L1 is a 
lipid accumulating subline of the mouse embryonic fibroblast cell line 3T3, which was 
established roughly a decade earlier (Todaro GJ and Green H 1963).  
 
A common way to achieve adipogenesis in preadipocytes is to use a mixture of either a 
hyper-physiologic concentration of insulin or a physiologic concentration of insulin-like 
growth factor 1 (IGF-1), a cyclic adenosine mono phosphate (cAMP) rising substrate, a 
glucocorticoid (GC) analog, such as dexamethasone, and calf serum (Figure 2.) (Scott 
MA et al. 2011). 
 
A rise in cAMP and the subsequent activation of an adipogenic transcription cascade in 
preadipocytes can be achieved either by increasing cAMP synthesis with e.g. forskolin, 
by inhibiting cAMP breakdown with e.g. 3-isobutyl-1-methylxanthine (IBMX) or simply 
by adding permeable analogues of cAMP itself to a confluent preadipocyte cell culture 
(Schmidt, W et al. 1990). cAMP gives rise to protein kinase A (PKA) levels which in turn 
leads to phosphorylation and consequent activation of cAMP responsive element binding 
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protein (CREB) (Gonzalez GA and Montminy MR, 1989). Also insulin has been 
suggested to be in part responsible for the phosphorylation of CREB through activation 
of mitogen-activating protein kinase (MAPK), which in turn phosphorylates CREB 
(Klemm DJ et al. 2001). In practice, the phosphorylation of CREB happens rapidly (≤ 5 
minutes) after the induction of differentiation (Zhang JW et al. 2004). CREB on its behalf 
activates the expression of C/EBPβ. The early expressed (≤ 4h after induction) C/EBPβ 
is bound to a corepressor complex, containing mSin3A and histone deacetylase 1 
(HDAC1), and lacks its DNA-binding ability, which is crucial for the transcription 
cascade to proceed (Wiper-Bergeron N et al. 2003; Tang QQ et al. 2005). The 
displacement from the corepressor complex is mediated by the ligand binding domain of 
an activated GC receptor. The DNA-binding activity of C/EBPβ results from double 
phosphorylation of the molecule. The firs phosphorylation, by MAPK, a known down-
stream target of insulin pathway, at Thr-188, occurs immediately after C/EBPβ itself is 
expressed and primes the molecule for the second phosphorylation (Klemm DJ et al. 
2001; Tang QQ et al. 2005). The second phosphorylation, by glycogen synthase kinase 3 
β (GSK3β) at either Ser-184 or Thr-179, occurs 12-14h after induction and only after this 
can C/EBPβ act as a transcription factor through binding the promoter region of its target 
genes. Concurrently with the obtainment of the DNA-binding ability of C/EBPβ, the 
formerly growth arrested cells enter the S-phase of the cell cycle and undergo several 
rounds of mitosis - a phase referred to as mitotic clonal expansion (MCE) -, a process that 
is dependent on the dual phosphorylated C/EPBβ and is obligatory for adipogenesis (Tang 
QQ et al. 1999; 2003; 2005). 
 
Another member of the C/EBP-family, C/EBPδ, is also expressed coincidently with 
C/EBPβ (Tang QQ and Lane MD 1999). The similarity of the two reaches beyond the 
expression pattern as both undergo the same phosphorylation steps and have same 
functions as shown by in-vivo knock-out studies elucidating that one can cover for the 
other and, that only by knocking both out, gets the adipogenic process clearly disturbed 
(Tanaka T et al. 1997; Tang and Lane MD 1999). It has been shown that dexamethasone 
- a potent GC receptor agonist and a typical agent used to induce adipogenesis in 
preadipocytes - increases the expression of C/EBPδ (Cao Z et al. 1991) 
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The role of C/EBPβ in MCE is further validated by the correlation of histone H4 
expression and the sequential phosphorylation of C/EBPβ (Zhang YY et al. 2011). The 
promoter regions of histone H4, a key player in MCE, have binding sites for C/EPBβ and 
by disturbing C/EPBβ with either small interfering RNA (siRNA) or with knocking out 
C/EPBβ with overexpression of a dominant negative C/EPB protein, the gene expression 
of histone H4 is down-regulated and the cells stay arrested in the G1 phase of the cell 
cycle. Moreover, the brake down of cyclin dependent kinase inhibitor p27, an obligatory 
step for the cells to enter the cell cycle, is dependent of a functional C/EPBβ as 
demonstrated with forced expression of a dominant negative C/EPB, A-C/EPB (Patel YM 
and Lane MD 2000; Zhang JW et al. 2004). 
 
Next on in the transcription cascade are C/EPBα and PPARγ (Clarke SL et al. 1997; Zuo 
Y et al. 2006). Both of these genes have a C/EBP binding site in their promoter region 
(Christy TJ et al. 1991; Zhu Y et al. 1995). It seems that PPARγ is required for the 
transcriptional activation of C/EBPα and once expressed C/EBPα keeps the transcription 
of the two ongoing by binding to the C/EBP binding sites in the promoter regions of the 
two. (Zuo Y et al. 2006). 
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Figure 2. Terminal adipogenesis and the role of a typical induction mixture. Firs, IBMX or some other 
cAMP inducing agent gives rise to cAMP. cAMP activates PKA which in turn activates CREB by 
phosphorylation. It is possible that also MAPK - a down-stream target of insulin pathway - activates CREB. 
CREB on its behalf activates the expression of C/EBPβ. CEBPβ then gets activated through double 
phosphorylation by MAPK and CSK3β. An activated GC receptor detaches C/EBPβ from a corepressor 
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complex (HDAC1/mSin3A). The fully active C/EBPβ then pushes the cells in to mitotic clonal expansion 
after which it activates PPARγ, C/EBPα and SREB1c. CEBPα on its behalf makes a positive feedback-loop 
by auto-transcribing itself and by further upregulating the transcription of PPARγ and SREB1c. 
(Gonzalez GA and Montminy MR, 1989; Schmidt, W et al. 1990; Christy TJ et al. 1991; Zhu Y et al. 1995; 
Clarke SL et al. 1997; Tang QQ et al. 1999; Klemm DJ et al. 2001; Tang QQ et al. 2003; Wiper-Bergeron 
N et al. 2003; Zhang JW et al. 2004; Tang QQ et al.2005; Zuo Y et al. 2006; Payne VA et al. 2010; Scott 
MA et al. 2011). (cAMP = Cyclic adenosine monophosphate; C/EBPα/β = CCAAT-enhancer-binding 
protein α/β; CREB = cAMP response element-binding protein; GC = (activated) glucocorticoid receptor; 
GSK3β = Glycogen synthase kinase 3 β; HDAC1 = Histone deacetylase 1; mSin3A = a corepressor; IBMX 
= 3-isobutyl-1-methylxanthine; IGF1 = Insulin-like growth factor 1; MAPK = Mitogen-activated protein 
kinase; PKA = Protein kinase A; PPARγ = Peroxisome proliferator-activated receptor γ). 
 
C/EBPα is antimitotic and either its premature or postponed expression would cause 
problems with the MCE phase (Wang H. et al. 2001). Indeed, in addition to the delay in 
the activation of the early expressed C/EBPβ, two different factors, AP-2α and Sp1, 
prevents C/EBPβ from transactivating the C/EBPα gene in preadipocytes (Jiang MS et al. 
1998; Tang et al. 1999). Both AP-2α and Sp1 are down-regulated in response to 
adipogenic induction. 
 
C/EBPα and PPARγ are key regulators of adipogenesis as many adipocyte genes are 
transactivated by the two (Christy RJ et al. 1989; Tontonoz P et al 1995; Schoonjans K et 
al 1996) and as forced expression of C/EBPα induces adipogenesis in the absence of 
hormonal induction (Lin F-T and Lane MD 1994). In addition, NIH-3T3 mouse 
fibroblastic cells – normally incapable to undergo adipogenesis even when hormonally 
induced – undergo adipogenesis under forced expression of either PPARγ or C/EBPα 
(Freytag S et al. 1994; Tontonoz P et al. 1995). Also, gene knock out studies have shown 
that in-vitro adipogenesis is blocked if either C/EBPα or PPARγ is knocked out (Lin F-
T. and Lane M.D. 1992; Ren D. et al. 2002).  
 
Also a third adipogenic transcription factor is expressed at least in part in response to the 
C/EBPs, sterol-regulatory-element-binding protein 1c (SREBP1c) (Payne VA et al. 
2010). SREBP1c upregulates the transcription of leptin and fatty acid synthase (FAS) in 
response to insulin, and as such it plays a role in insulin sensitivity and both energy- and 
lipid homeostasis (Kim JB et al. 1998). Consistently, the subcutaneous fat of people with 
type 2 diabetes has markedly diminished SREBP1c expression (Ducluzeau PH et al. 
2001; Sewter C et al. 2002). 
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3.3  Adipose tissue 
 
The human adipose tissue composes of a variety of different cell types e.g. adipocytes, 
preadipocytes, blood cells, vascular tissue and ATRICs (Rodbell M 1964; Hauner H et 
al. 1989; Weisberg SP et al. 2003; Lumeng CN et al. 2008).  
 
The ATRICs include cells from both the innate- and the adaptive immune system and 
they have been linked in obesity related comorbidities, such as the metabolic syndrome 
and type II diabetes (Lumeng CN et al. 2008; Wentworth JM et al 2010). The main change 
seen in the ATRICs composition during obesity, is the rise in macrophage count and their 
phenotypic shift form an anti-inflammatory type 2- (M2) to an inflammatory type 1 
macrophage (M1). M1s secrete tumor necrosis factor-α (TNF-α), which in turn 
downregulates the Glucose transporter type 4 (GLUT4) and inhibits insulin signaling 
(Lumeng CN et al. 2007). Several factors in obesity drives this change in macrophage 
phenotype: first, lipid spillover and the subsequent extracellular appearance of free 
saturated fatty acids induce inflammation through endoplasmic reticulum stress, 
activation of toll like receptor 4 (TLR-4) mediated pathways and active cytokine cleavage 
by inflammasome induction (Suganami T et al. 2007; Erbay E et al. 2009; Saberi M et al. 
2009; Vandanmagsar B et al. 2011). Second, obesity is also correlated with an increase 
of lipopolysaccharide (LPS) in the plasma (Cani PD et al. 2007). LPS is a known bacterial 
danger signal for the innate immune system. Third, the secretion of adiponectin, a well-
known M2-polarizing adipokine, is reduced in metabolic syndrome, resulting in increased 
M1 polarization (Devaraj S et al. 2008; Ohashi K et al 2010). 
 
While this part of the immune system seems irrational and rather ectopic, it has been 
hypothesized that the role of this coexistence of ATRICs and adipocytes is to form a 
functional immuno-metabolistic ensemble that controls energy balances in response to 
bacterial infections and parasitic infestations (Chawla A et al. 2011). In case of a bacterial 
infections it is convenient to steer excess energy from tissues towards the blood for the 
use of white blood cells by inducing insulin resistance in muscle and adipose tissue (T 
helper 1 -type inflammatory response), whereas in case of a parasitic infestation it is of 
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paramount importance to deprive energy from the parasite, which can be achieved by 
means of insulin sensitizing (T helper 2 -type inflammatory response). 
 
3.4 Adipokines 
 
According to Rosen and Spiegelman, adipokines, such as leptin, adiponectin and resistin 
(among others) are “adipose-derived secreted molecules” (Rosen ED and Spiegelman BM 
2006). The role of adipokines concern regulation of energy balance and glucose 
homeostasis and is best understood in the case of leptin (Fei H et al. 1997; Watterson KR 
et al 2012). High levels of leptin receptors are found in the mediobasal hypothalamus, 
where their activations leads to up-regulation of anorexigenic and down-regulation of 
orexigenic pathways, resulting in down-regulation of food intake. In addition, leptin 
increases glucose transport in muscles and insulin sensitivity in liver through both central 
(via hypothalamic circuits) and peripheral (local leptin receptors in liver and muscle) 
mechanisms (Berti L et al. 1997; Berglund ED et al. 2012). 
 
In addition to adipose specific adipokines, a variety of more common cytokines are also 
produced in the adipose tissue, such as angiotensinogen, vascular endothelial growth 
factor (VEGF) and TNFα (Aubert J et al. 1997; Sarkanen J-R et al. 2012). 
 
3.5 Human adipose tissue derived stem cells 
 
In contrast to other MSC sources, such as the bone marrow, the human adipose tissue 
serves as an easy and abundant source (Zuck PA et al. 2002). The gathering of the MSCs 
from the adipose tissue includes less invasive surgical procedures than from the other 
sources and as such enables for example relatively easy autologous stem cells treatment. 
The differentiation potential of these cells is rather versatile, including adipogenic, 
chondrogenic, myogenic, and osteogenic and even neurogenic pathways in the presence 
of the right differentiation factors (PA Zuk et al. 2001; KM Safford et al. 2002). While in 
rats there have been shown to be depot specific differences in the differentiation potential 
and yield of adipose derived stem cells (ASC), in human ASCs (hASC) depot specific 
12 
 
differences have only been found concerning the yield (JK Frazer et al. 2007; WJFM 
Jurgens et al. 2008; HS-V Gijsen et al. 2012). 
 
3.6 Human adipose tissue extract 
 
Sarkanen and colleagues have come up with a method to produce a cell-free adipose tissue 
extract (ATE) that composes of a variety of adipo- and angiogenic growth factors 
including VEGF, basic fibroblast growth factor (bFGF), interleukin-6 (IL-6), adiponectin, 
angiogenin, leptin, and IGF-I, as well as lower levels of a wide variety of other cytokines 
(Sarkanen J-R et al. 2012). The adipogenic potential of ATE has been tested in-vitro and 
the results show great, dose-dependent adipogenic potential marked as increased 
triglyceride accumulation within a week of culture with a concentration as low as 
200µg/ml and elevated adipocyte differentiation markers starting from 350µg/ml. Using 
1mg/ml of ATE gives increased and accelerated accumulation of triglycerides when 
compared to the common adipogenic induction media consisting of dexamethasone, 
insulin and IBMX, among other things. Also the rise in PPARγ levels are even 7 fold 
when using 1200-1500µg/ml of ATE in comparison with the same control. In addition, 
the extract possesses angiogenic potential which is of great advantage concerning 
possible tissue engineering applications. More even, as the extract is cell-free not only 
autologous, but allogenic use is also possible.  
 
 
4 ENDOCRINE DISRUPTING CHEMICALS 
 
According to Annamalai and Namasivayamso, EDCs are “exogenous agents that interfere 
or disrupt the normal synthesis, secretion, transportation, binding and metabolism of 
natural hormones” (Annamalai J and Namasivayam V 2015). Some examples of EDSs 
affecting adipogenesis are organotin compounds, such as tributyltin (TBT), used as 
stabilizers in plastics and as biocides, phthalates, such as bis(2-ethylhexyl)phthalate 
(DEHP), used as plasticizers, and bisphenols, such as BPA, used to make endurable clear 
plastics for everyday use, such as water bottles (Hurst CH and Waxman DJ 2003; le Maire 
A 2009; Biemann R et al 2012). All these are found in effective concentrations in our 
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environment and plasma due to their strikingly low lowest-observed-adverse-effect levels 
(LOAEL). 
 
Both TBT and DEHP have shown positive adipogenic properties in murine pre-adipocyte 
in-vitro cell studies and the proposed mechanism of action for both is PPARγ agonism 
(Biemann R et al. 2011). 
 
BPA is a monomer that was originally developed as a synthetic estrogen, but as it was 
found to be 37 000 times weaker than the natural estradiol, it was never used as a drug 
(Dodds EC and Lawson W 1936). Instead, the plastic and paper manufacturing industries 
has used it widely ever since, and nowadays it is used for example in lining of plastic and 
stainless steel bottles and aluminum cans and in paper products, mainly thermal paper, 
because of which it can also be found in recycled paper products, such as toilet paper 
(Cooper JE et al. 2011; Le HH et al. 2008; Liao C and Kannan K 2011). Due to all of 
these exposure source, detectable levels of BPA can be found in <90% of the US 
population, which is alarming because BPA exposure has been linked for example to 
increased risk of miscarriages, obesity, and cancer (Calafat AM et al. 2008; Rochester JR 
2013).  
 
BPA have been studied in cell culture and it has shown adipogenic potential in both 
murine and human in-vitro cell models, though one murine in-vitro study showed anti-
adipogenic results (Masuno H et al. 2005; Sargis RM et al. 2010; Biemann R et al. 2012; 
Ohlstein JF et al. 2014). Several different mechanism of actions have been proposed, 
involving phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-kinase)-, GC-, and 
estrogen receptor (ER) pathway.  
 
Some contradicting data concerning the true effect on obesity of these substances is 
available: when these substances are tested in-vitro as a mixture, the 
adipogenic/antiadipogenic effects ceases to exist, possibly due to the overlapping actions 
of the chemicals (Biemann R et al. 2014). 
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5. AIMS OF THE STUDY 
 
This study was a part of a project that aims at creating a test system that presents the 
properties of a chronically inflamed adipose tissue, thus mimicking the adipose tissue 
found in obese individuals. In the test system, a natural adipogenesis inducer, ATE was 
used.  Two separate aims where set for this specific study.  
 
1) The first aim was to compile a set of chemicals acting as pro- or antiadipogenic 
agents on hASCs. The set was to be composed of chemicals affecting different 
sites of action in the adipogenesis transcription pattern with emphasis on the 
currently occurring obesity epidemic.  
 
2) The second and the main aim of the study was to explore and optimize the test 
system, to study possible adipogenic- or antiadipogenic effects of the agent of 
interest, BPA. Concentrations of the chemical, the time-window and length of 
chemical exposure and suitable ATE concentrations were to be studied in practical 
laboratory work. 
 
 
6. MATERIALS AND METHODS 
 
Ethics: with permission from the Ethics Committee of the Pirkanmaa Hospital District, 
Tampere, Finland (R03058, Ylikomi et al).  
 
The manufacturers of the used equipment is mentioned in Appendix I: Materials 
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6.1 Process flow charts (PFCs) 
 
6.1.1 PFC 1 
 
Day 0 Human adipose stem cell thawing from the master bank 
Start of hASC culture 
 
 
 
 
Day 7 hASC plating 10 000 cells/cm2 into 96 -well plates 
   
 
 
 
Day 8 1. Induction of adipogenesis with ATE inductive medium and/or possible BPA exposure 
 
 
 
 
 
Day 9  Cytotoxicity test (Neutral Red Uptake assay) 
 
 
 
 
Day 11 2. Induction of adipogenesis with ATE inductive medium and/or possible BPA exposure 
 
 
 
 
Day 14 Oil-Red-O staining 
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6.1.2 PFC 2 
 
 
Day 0 Human adipose stem cell thawing from the master bank 
Start of hASC culture 
 
 
 
 
Day 7 hASC plating 10 000 cells/cm2 into 96 -well plates 
  
 
 
 
Day 8 BPA exposure 
 
 
 
 
Day 13 1st adipogenic induction 
 
 
 
 
Day 16 2nd adipogenic induction 
 
 
 
Day 19    Oil-Red-O extraction and analysis of results 
 
 
6.2 hASC isolation 
 
Human adipose tissue specimens were cut into small pieces and enzymatically digested 
with 0.05% collagenase I in DMEM/F12 for 60 min at 37°C in a gyratory water bath. The 
digested tissue was centrifuged at 600 g for 10 min at room temperature. Finally, the 
digested tissue was filtered through a 100 mm filter, after which the cells were seeded in 
to a 75 cm2 culture flask. 
 
6.3 hASC culture 
 
hASCs were cultured in 10 ml of hASC culture medium (HCM) (DMEM/F12 
supplemented with 10-15% human serum and 1% L-glutamine) in 75 cm2 cell culture 
flasks in cell culture incubator at 37°C at 5% CO2. The culture time was between 4 to 7 
days after a vial of frozen hASC was thawed from the master bank. For the adipogenesis 
induction, the cells were seeded at a density of 10 000 cells/cm2 into 96 -well plates in 
HCM.  
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6.4 Adipogenic induction 
 
After plating the cells in-to 96-well plates two separate adipogenic inductions were 
performed.  The induction medium consisted of HCM, 1% penicillin/streptomycin with 
or without a low (250µg/ml) or high (1000µg/ml) concentration of ATE. In each study, 
two inductions were made. The inductions were done either on days 8 and 11 (studies 1 
to 5) or 13 and 16 (study 6). The cells were exposed to the induction medium for seven 
days before Oil-Red-O (ORO) staining. 
  
6.5 Chemical exposure 
 
BPA was used as a test item in the assay optimization. As BPA has previously shown 
both pro- and antiadipogenic properties, it was studied for both effects separately 
(Masuno H et al. 2005; Sargis RM et al. 2010; Biemann R et al. 2011; Ohlstein JF et al. 
2014). The adipogenic effect was studied with HCM only and with the low concentration 
of ATE (to get a possible synergistic effect showing) while the antiadipogenic effect was 
studied with the high concentration of ATE. To see if BPA had different effects in 
different phases of adipogenic development of the hASCs, a set of test were performed, 
where BPA was introduced five days before the ATE induction, or only during the first 
or the second ATE induction. 
 
These parameters were tested in seven different studies, in all of which the used BPA 
concentration where 0.05µM, 0.1µM, 0.5µM, 1µM, 5µM, 10µM, 50µM, 100µM. For 
every used concentration and control, a set of 6 parallels (n=6) were used. 
 
6.6 Used concentrations and controls 
 
BPA concentrations used in the study: 
0.05µM, 0.1µM, 0.5µM, 1µM, 5µM, 10µM, 50µM, 100µM 
 
Controls used in the study: 
HCM control (0 ATE) 
250µg/ml of ATE control (250 ATE) 
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1000µg/ml of ATE control (1000 ATE) 
2000µg/ml of ATE control (2000 ATE) 
 
All of the above may have been used as a negative- or a positive control. A negative 
control referring to the exact same base liquid as the one used in the BPA containing 
mixtures, but just whitout BPA. For example, if the test is about the effects of different 
concentrations of BPA, when applied simultaneously with 1000µg/ml of ATE, the 
negative control used, is 1000ATE. The posiive control is referring to a known adipogenic 
dose of ATE, being either 1000ATE or 2000ATE. 
 
6.7 Evaluating the cytotoxicity of BPA 
 
Before using BPA in the adipogenesis assay, a neutral red uptake (NRU)-cytotoxicity test 
was performed to ensure that only non-cytotoxic dosages of the chemical were used.  
 
The test was performed as described before (Repetto G et al. 2008). Briefly, 24 hours 
after exposure to BPA, the medium was removed and the cells washed with preheated 
phosphate-buffered saline (PBS). 250 µl of Neutral Red (NR) medium (25 mg of Neutral 
Red dye in one ml of hASC culture medium) was added into the wells which then were 
incubated for two hours at 37°C. After incubation, the NR-medium was removed and the 
cells washed with 250 µl of PBS. Then a 100 µl of NR-desorption medium (50% EtOH, 
1% acetic acid in H2O) was added into the wells and incubated in a shaker for 20 min, 
protected from light. After shaking, the wells were allowed to settle down for five 
minutes. The absorbance was then measured at 540 nm with spectrophotometry. 
Concentrations allowing at least 80% of the cells to maintain viability in the assay were 
considered non-cytotoxic. 
 
For every used BPA concentration, a set of 4 parallels (n=4) were used. Also, a 0 ATE 
control was tested, for which a set of 8 parallels (n=8) was used. 
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6.8 Evaluating triglyceride accumulation in hASCs 
 
ORO staining and extraction: After seven days of adipogenic induction the lipid 
accumulation was assessed using ORO staining. 
 
In advance, a 0.5% ORO stock solution had been prepared using 100% isopropanol as a 
solvent. At the time of staining, the stock solution was diluted 3:2 in distilled water, left 
at room temperature for 10 minutes and then filtered through a standard filter paper. 
The cells were fixed using 4% paraformaldehyde for 20 minutes. 
The cells were then exposed to 60% isopropanol for two to five minutes, followed by the 
ORO staining solution for five minutes. The cells were then rinsed with PBS after which 
they were left to dry. The next day, the ORO was extracted from the cells using 100% 
isopropanol and a shaker adjusted to 180 rpm for 10 minutes. (Between the different steps 
of the staining PBS was used to rinse.) 
 
Photometric measurement was performed using VarioskanFlash (Thermo Scientific, 
Finland, software version 4.) at wavelength of 540 nm. 
 
6.9 Statistics 
 
The results were processed with Microsoft Excel 2013, IBM SPSS statistics 22. Statistical 
differences were determined by ANOVA, followed by the post-hoc Dunnett t (2-sided). 
Test was run for the obtained absorbance values comparing the mean absorbance value 
(mv) given by the different studied BPA concentrations against the mv of a negative 
control. A significance level of 0.05 was used (p<0.05 = *; p<0.01 = **; p<0.001 = ***). 
 
 
7. RESULTS 
 
All the test results are found in detail in Appendix II: Test Results 
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7.1 Model chemicals  
 
Chemicals acting on different steps of adipogenesis were searched from Medline- and 
ScienceDirect databases. In addition to EDSs mentioned in chapter 5 of this paper, a 
group of pharmaceuticals and a research chemical, acting through SREBPs, GC and 
TNFα, were selected as possible test items (Table 1). In some of the cases an in-vivo effect 
on adipose tissue is commonly seen, whereas in some, the main target of the substance 
plays a crucial role in adipogenesis. The first group should be interesting to study with a 
fully functioning cell culture-assay, whereas the substances of the latter one would serve 
as convenient reference substances. 
In the first group with the EDCs are the antiretroviral drug, lopinavir and the 
antipsychotic, olanzapine. Both of these substances are used chronically and adipose 
tissue alterations are more or less evident among the patient groups of both medicines 
(Capanni C et al. 2005; Yang LH et al. 2007; Hudon SE et al. 2008). The users of lopinavir 
suffer from lipodystrophy and type II diabetes, whereas the users of olanzapine suffer 
from obesity and metabolic syndrome. The effects of lopinavir might be explained with 
the inhibition of the farnesylated-proteins converting enzyme 1 (FACE1) and its 
downstream target SREBP1a. In case of olanzapine, the effects might be, at least in part, 
explained by upregulation of SREBP1 expression, but the fact that olanzapine inhibits the  
histamine 1 receptor (H1) in  the central nervous system, probably has its own toll on the 
patients whole energy balance, as H1 is crucial in regulating the feeling of satiety (Kroeze 
WK et al. 2003).  
 
The rest of the chemicals, CP-394531, JTP-426467 and etanercept are known inhibitors 
of the GC, PPARγ and TNFα receptors, respectively (Morgan BP et al. 2002; Nishiu J et 
al. 2006; European Medicines Agency - summary of product characteristics of Enbrel 
(etanercept) 25mg powder and solvent for solution for injection). Thus, they could serve 
as reference substances in addition of being valuable in the study of the steps of human 
adipogenesis, etanercept having a special indication in studying a co-culture of 
macrophages and adipocytes.  
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Table 1. Model chemicals. 
Chemical name Supposed mechanism of 
action 
Supposed effect on the 
test system 
Indication / use 
BPA PI3-kinase-, ER- and GC 
pathways. (1) 
Adipogenic or 
antiadipogenic 
Plastics 
TBT  RXR- and PPARγ 
pathways. (2) 
Adipogenic Agricultural fungicide / 
Plastics 
DEHP PPARγ and -α pathways. 
(2) 
Adipogenic Plastics 
Lopinavir Inhibition of FACE1 and 
its downstream target 
SREBP1a. (3) 
Antiadipogneic  A pharmaceutical used 
for treatment of HIV-
infection 
Olanzapine Upregulation of SREBP-
1 expression. (3) 
Adipogenic A pharmaceutical 
(an anti-psychotic agent) 
CP-394531 GC receptor antagonism. 
(4) 
Antiadipogenic A research chemical 
JTP-426467 PPARγ agonism. (5) Adipogenic A research chemical 
Etanercept TNF- α-antagonism. (6) An insulin sensitizing 
effect in a co-culture of 
hASCs and 
macrophages.  
A pharmaceutical used 
as an 
immunosuppressant 
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BPA = Bisphenol A; DEHP = Bis(2-ethylhexyl) phthalate; ER = Estrogen receptor; FACE1 = farnesylated-
proteins converting enzyme 1; GC = glucocorticoid receptor; hASC = human adipose derived stem cell; 
PI3-kinase = phosphatidylinositol-4,5-bisphosphate 3-kinase; PPARγ/α = peroxisome proliferator-
activated receptor γ/α; RXR = retinoid X receptor; SREBP 1/1a = sterol-regulatory-element-binding protein 
1/1a; TBT = tributyltin; TNF-α = tumor necrosis factor-α. 
(1) Masuno H et al. 2005; Sargis RM et al. 2010; Biemann R et al. 2011; Ohlstein JF et al. 2014. (2) 
Biemann R et al. 2011. (3) Capanni C et al. 2005; Yang LH et al. 2007; Hudon SE et al. 2008. (4) Morgan 
BP et al. 2002. (5) Nishiu J et al. 2006. (6) European Medicines Agency - summary of product 
characteristics of Enbrel (etanercept) 25mg powder and solvent for solution for injection. 
 
7.2 Is BPA cytotoxic? 
 
None of the used BPA concentrations was cytotoxic (Table 2.) 
 
Table 2. Neutral red uptake assay results. 
c Neg.ctrl. 0.05µM 0.1µM 0.5µM 1µM 5µM 10µM 50µM 100µM 
mv 0.1420 0.1453 0.1566 0.1331 0.1421 0.1462 0.1536 0.1357 0.1283 
% 100 102 110 94 100 103 108 96 90 
c= BPA concentration, Neg.ctrl. = HCM, mv= mean absorbance value, %= mv/mv (Neg.Ctrl) ration in 
percentages. 
 
7.3 Does BPA induce adipogenesis in hASCs? 
 
To find out if BPA is capable of inducing adipogenesis in hASCs, BPA was introduced 
to the cell culture in the HCM according to PFC 1 (Figure 3). The results were controlled 
with a negative (0 ATE) and a positive control (1000 ATE). 
 
When compared to the negative control, 0.05µM of BPA inhibited triglyceride 
accumulation significantly (mv=0.1562 p=0.033). 
 
(0 ATE mv: 0.2373) 
(1000 ATE mv: 0.3243) 
 
7.4 Does BPA have a synergistic effect with ATE? 
 
To find out if BPA has synergistic effects with ATE, BPA was introduced to the cell 
culture with 250µg/ml of ATE according to PFC 1 (Figure 4). The results were controlled 
with a negative (250 ATE) and a positive control (1000 ATE). 
 
24 
 
When compared to the negative control, 0.5µM of BPA inhibited triglyceride 
accumulation significantly (mv=0.2253 p=0.042) while 50mM of BPA significantly 
increased triglyceride accumulation (mv= 0.3508 p= 0.027).  
 
(250 ATE mv: 0.2862) 
(1000 ATE mv: 0.4415) 
 
7.5 Does BPA inhibit adipogenesis? 
 
To find out if BPA inhibits adipogenesis, BPA was introduced to the cell culture with 
1000µg/ml of ATE according to PFC 1 (Figure 5). The results were controlled with a 
negative (1000 ATE), HCM (0 ATE) and a positive control (2000 ATE). 
 
When compared to the negative control, BPA concentrations 0.05µM, 0.1µM, 0.5µM, 
1µM, 5µM and 50µM inhibited triglyceride accumulation significantly (mv=0.2245, 
0.2678, 0.2419, 0.3119, 0.2590, 0.2900 p=<0.001, <0.001, <0.001, 0.024, 0.001 
respectively). Still, When compared to the 0 ATE control a significantly higher 
triglyceride accumulation was seen with all studied BPA concentrations (p= <0.001 for 
all but 0.05µM and 0.5µM, for which p= 0.001 and 0.002 respectively). 
 
(0 ATE mv: 0.1529) 
(1000 ATE mv: 0.3803) 
(2000 ATE mv: 0.3558) 
 
7.6 Is the effect of BPA dependent on the exposure time-window? 
 
To find out if the exposure time-window of BPA had an effect on the outcome, four 
different tests were performed.  
 
1) To find out if BPA had a synergistic effect when introduced at the start of 
adipogenesis, BPA was introduced to the cell culture with 250µg/ml of ATE 
according to PFC 1, but only during the first induction (Figure 6). During the second 
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induction only 250µg/ml of ATE was used. The results were controlled with a 
negative (250 ATE) and a positive control (1000 ATE). 
 
When compared to the negative control, BPA inhibited triglyceride accumulation 
significantly with all the studied BPA concentrations (mv=0.1607, 0.1681, 0.1497, 
0.1592, 0.1689, 0.1604, 0.1575, 0.1542 p=0.003, 0.012, <0.001, 0.003, 0.013, 0.003, 
0.002, 0.001 respectively).  
 
(250 ATE mv: 0.2256) 
(1000 ATE mv: 0.3257) 
 
2) To find out if BPA had a synergistic effect when introduced later on at the early phase 
of adipogenesis, BPA was introduced to the cell culture with 250µg/ml of ATE 
according to PFC 1, but only during the second induction (Figure 7). During the first 
induction only 250µg/ml of ATE was used. The results were controlled with a 
negative (250 ATE) and a positive control (1000 ATE). 
 
When compared to the negative control, BPA inhibited triglyceride accumulation 
significantly with BPA concentrations 0.05µM, 0.5µM, 1µM, 5µM, 10µM, 50µM 
and 100µM (mv=0.2161, 0.1896, 0.1833, 0.2179, 0.1992, 0.1887, 0.2249 p=0.012, 
<0.001, <0.001, 0.015, 0.001, <0.001, 0.037 respectively.) while BPA concentration 
0.1µM showed no statistical significance. Notably, the mv of the 250 ATE was not 
significantly lower than of the 1000 ATE. 
 
(250 ATE mv: 0.2856) 
(1000 ATE mv: 0.3285) 
 
3) To find out if BPA had a synergistic influence on adipogenesis when introduced to 
the hASCs before the induction, BPA was introduced to the cell culture five days 
before the first induction, according to PFC 2 (Figure 8). The results were controlled 
with a negative (250 ATE), HCM (0 ATE) and a positive control (1000 ATE). 
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The test cells as well as the negative control cells had 250µg/ml of ATE during both 
inductions, while the 1000 ATE cells had 1000µg/ml of ATE and the 0 ATE cells 
HCM throughout all the test. 
 
When compared to the negative control, no statistical significance was see with any 
of the BPA concentrations used. Notably, the mv of the 250 ATE was slightly but not 
significantly lower than of the 0 ATE. 
 
(0 ATE mv: 0.3400) 
(250 ATE mv: 0.3080) 
(1000 ATE mv: 0.4214) 
 
4) To find out if BPA inhibits ATE induced adipogenesis, when introduced to the hASCs 
before the adipogenic induction, BPA was introduced to the cell culture five days 
before the first induction, according to PFC 2 (Figure 9). The results were controlled 
with a negative (1000 ATE) and a HCM control (0 ATE). The test cells as well as the 
negative control cells had 1000µg/ml of ATE during both inductions. The 0 ATE cells 
had only HCM throughout all the test.  
 
When compared to the negative control, BPA inhibited triglyceride accumulation 
significantly with concentrations 1µM, 5µM, 10µM, 50µM and 100µM (mv=0.3256, 
0.3079, 0.3353, 0.3247, 0.2900 p= 0.001, <0.001, 0.004, 0.001, <0.001 respectively). 
Notably, the 0 ATE mv was not significantly lower that of the 1000 ATE. Thus, even 
When compared to the HCM control BPA seemed to inhibit triglyceride accumulation 
significantly with concentrations 5µM and 100µM (p= 0.044 and 0.005 respectively).  
 
(0 ATE mv: 0.3738) 
(1000 ATE mv: 0.4222) 
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Figure 3. Adipogenic potential of BPA. mv= mean absorbance value, c= BPA concentration, 
neg.ctrl= 0 ATE. 
 
 
Figure 4. Synergistic effect of BPA. mv= mean absorbance value, c= BPA concentration, 
neg.ctrl= 250 ATE. 
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Figure 5. Antiadipogenic effect of BPA. mv= mean absorbance value, c= BPA concentration, 
neg.ctrl= 1000 ATE, HCM= 0ATE. 
 
 
 
 
Figure 6. Synergistic effect of BPA when introduced at the start of adipogenesis. mv= mean absorbance 
value, c= BPA concentration, neg.ctrl= 250 ATE. 
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Figure 7. Synergistic effect of BPA when introduced later on at the early phase of adipogenesis. mv= mean 
absorbance value, c= BPA concentration, neg.ctrl= 250 ATE. 
 
 
Figure 8. Synergistic effect of BPA, when introduced before adipogenic induction. mv= mean absorbance 
value, c= BPA concentration, neg.ctrl= 250 ATE, HCM= 0 ATE. 
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Figure 9. Antiadipogenic effect of BPA, when introduced before adipogenic induction. mv= mean 
absorbance value, c= BPA concentration, 
neg.ctrl= 1000 ATE, HCM= 0 ATE. 
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8. DISCUSSION 
 
BPA showed no significant adipogenic nor synergistic potential in any of the studies, with 
the exception of the 50µM dose given with 250ATE (Figure 2). This particular result 
contradicts with the values seen when BPA was given, again with 250 ATE, but only in 
the early or the late phase of adipogenesis (Figures 4 and 5). These results have more 
conformity concerning the other BPA concentration, thus it seems that the solely 
adipogenic result is due to a humane mistake, probably during the washout of the ORO 
staining solution. Similarly, the solitary antiadipogenic result seen with BPA 
concentration of 0.5µM, given with HCM only, makes no sense, and is thus, probably a 
consequence of detachment of cells during ORO-staining. Also, the irrationally high mv 
given by a 0 ATE control, seen in Figure 7, is probably a consequence of some kind of 
mix-up during the lab work, presumably during the inductions. 
 
On the other hand, a slight tilt towards an antiadipogenic effect was seen throughout all 
the studies. When the cells were exposed to BPA with 1000 ATE, a clear inhibition in 
triglyceride accumulation was seen, though no dose-dependence occurred (Figure 3). 
Moreover, inhibition in triglyceride accumulation was seen even when BPA was given 
with an only minutely adipogenic dose of 250 ATE as base treatment (Figures 4 and 5). 
And coherently with the trend, when BPA was introduced to the hASCs before a high 
dose of ATE, BPA showed clearly inhibitory effects on triglyceride accumulation – one 
could argue, that even in a dose dependent manner. 
 
The fact, that no significant effect was seen when BPA was introduced before a low dose 
of ATE, is probably explained by the too small effect a 250µg/ml dose of ATE has on 
hASCs.  
 
The antiadipogenic effects seen in this study, are somewhat coherent with the ones seen 
in the work of Biemann and co-workers, conducted with rodent C3H/10T1/2 cell line 
(Biemann R et al. 2012).  
 
In another study, conducted by Ohlstein and coworkers, BPA showed adipogenic effects 
on hASCs (Ohlstein JF et al. 2014). In this study, an estrogenic effect was proven to be 
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the mechanism of action. Ohlstein’s study was also conducted using hASCs and thus the 
results of the present study should have had more in common with this study, than with 
Biemann’s rodent based study. No clear reason is to be found for the contradiction 
between the results from Ohlstein’s and this study, though some wide speculations can 
be made. 1) The induction media used by Ohlstein was more of a traditional induction 
adipogenic induction media, consisting of few basic synthetic components and bovine 
serum, whereas ATE is a highly complex, biological mixture. The possibility that BPA 
had some, either chemical or physiological, interactions with one or more components in 
ATE could explain the inability of BPA to induce adipogenesis in the present study. 2) 
Ohlstein and co-workers normalized their mv to the protein levels with a bicinchoninic 
acid assay. Even though the used cell count and the composition of ATE were 
standardized, controlling the cell culture and cell staining procedures with protein 
normalization would have been a good thing, keeping in mind, that the present study was 
conducted by an unexperienced researcher. Though, the fact that only one out of eight 
BPA concentration in one out of seven studies showed any adipogenic effects makes it 
quite unlikely that a adipogenic effect would have existed anyhow. 3) The length of the 
adipogenic induction and the exposure to BPA in the present study was two to three times, 
7 to 14 or 21 days, shorter than that of Biemanns. If the adipogenic effect of BPA is due 
to estronergic properties of the substance, it might not have had enough time to have a 
phenotypic effect. In fact, in the study of Ohlstein and co-workers, the increase in 
estrogenic RNA expression is registered only after seven days of induction. No RNA 
expression test was performed in the present study. 
 
 
9. CONCLUSIONS 
 
A great deal is to be done to achieve the final goal, a fully functional, obesity mimicking 
adipogenic cell model. Still, the study of adipogenesis, by using humane stem cells and 
adipogenic induction media, is closer to the truth, if we want to gather data concerning 
human adipogenesis. If, for instance, the adipogenic effects of BPA seen in Biemanns 
study, did not show in the present study because of the used induction media, ATE, the 
fact is, that the result from the present study, would be closer to the truth – that is, the 
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effects of BPA on adipogenesis, in-vivo. Still, some shortcomings of ATE, such as batch-
to-batch variance, ATE have to be overcome in the future.  
What comes to the execution of the study, some easily fixed issues occurred. 1) The 
planning of the study was biased towards an adipogenic effects due to the assumptions 
concerning BPAs effects on human health. That is, most of the studies were done with 
the 250 ATE concentration, as get an adipogenic effect visible. More studies should have 
been made with a base ATE concentration of 1000µg/ml to get more data about the 
possible inhibitory effects on the triglyceride accumulation. Also, a HCM (0 ATE) control 
should have been along in every study, to see control the other controls. All and all, the 
ORO staining is a relatively easy way of getting quantitative information about 
adipogenesis, but it seems to be too unreliable when used without controlling the 
adipogenic process for example with . 
 
What comes to the possible flaws originating from the unexperienced hands, which 
conducted the study, the solution most surely lies in practice, practice, practice. 
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11. APPENDIX I: MATERIALS 
 
Oil-red-O (Sigma) 
100% isopropanol (Merck & Co., Inc., Whitehouse Station, NJ, USA)  
4% paraformaldehyde (Sigma) 
Collagenase I (Invitrogen) 
100 mm filter (Sarstedt) 
40 mm filter (Sarstedt). 
 
VarioskanFlash (Thermo Scientific, Finland, software version 4.) 
Microsoft Excel 2013, (Microsoft corporation) 
IBM SPSS statistics 22 (IBM) 
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12. APPENDIX II: TEST RESULTS 
 
In all the tests, Dunnett t-tests treat one group as a control, and compare all other groups 
against it. 
 
Chapter 8.3 Does BPA induce adipogenesis in hASCs? 
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Chapter 8.4 Does BPA have a synergistic effect with ATE? 
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Chapter 8.5 Does BPA inhibit adipogenesis? 
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Chapter 8.6 Is the effect of BPA dependent on the exposure time-window? 
Part 1) 
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Chapter 8.6 Is the effect of BPA dependent on the exposure time-window? 
Part 2) 
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Chapter 8.6 Is the effect of BPA dependent on the exposure time-window? 
Part 3) 
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Chapter 8.6 Is the effect of BPA dependent on the exposure time-window? 
Part 4) 
 
 
